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CHAPTER I 
 
 
 
INTRODUCTION 
 
Diabetes Mellitus 
 
Diabetes mellitus is the metabolic disorder affecting metabolism of carbohydrates, lipids, 
proteins in every type of cells in the body. This metabolic disorder is characterized by 
insensitivity to insulin, insufficient/absent insulin secretion, or both. Currently, around 
23.6 million people (7.8% of the population) are affected by this metabolic syndrome in 
the United States [1]. Moreover, more than 246 millions are estimated to have diabetes  
worldwide, and this number is expected to increase in the next few decades [2-4]. In the 
U.S alone, the cost of diabetes, including medical care and social costs, reached around 
$174 billion in the year of 2007 [5]. This cost is also expected to increase drastically in 
next few years, therefore diabetes mellitus is now considered as epidemic.  
 
There are several forms of diabetes. Among these cases of diabetes, type I and type II are 
the ones that affect most of the patients (95 to 99%). Type I diabetes (T1D) is caused by 
pancreas deficiency in insulin production [6, 7] whereas type II diabetes (T2D) is 
characterized by insulin resistance with deficiency in insulin secretion and hyperglycemia 
[8].  
 
T1D is triggered by the autoimmune β-cells (pancreas) failure in insulin production. 
Because immune system tries to destroy insulin releasing factors in pancreas, 90% of the 
patients suffering from T1D display signs of antibodies against insulin and β-cells [7]. 
Autoimmune destruction is caused by either genetic or environmental factors, however, 
the exact mechanism is not well characterized [9]. Many cases of T1D are found among 
children although some adults also develop pancreas failure. Essentially, T1D patients 
require periodic insulin injection to maintain proper glucose concentration in plasma 
since they cannot produce the hormone by themselves. 
. 
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T1D and T2D together comprise most of the population affected by diabetes. Only 5-10% 
of them have T1D.  T2D is the most commonly diagnose case of diabetes which accounts 
for 90-95% of diabetic patients in the U.S [1]. T2D patients develop the conditions in 
which body/cells do not properly respond to existing insulin over period of time.  T2D 
can be developed from multiple causes. These include high cholesterol, inactive lifestyle, 
high fat diet, and aging [3, 10]. However, to date the mechanisms by which people 
develop insulin resistance remain unclear.  
 
 
 
Type II Diabetes Mellitus 
 
Multiple factors seem to participate to the development of T2D although direct factors or 
the starting points of the T2D development are not characterized. The most prevalent 
condition induced by the development of insulin resistance is fasting hyperglycemia 
because of the lack of adequate response to insulin signaling in the cells to clear up 
glucose. Insulin resistance and hyperglycermia together define T2D. Individuals who 
have glucose concentration of more than 7.8mmol/L after 2 hours from food intake are 
considered to have developed insulin resistance and T2D. Insulin resistance in muscle 
and liver is most prevalent conditions account for glucose intolerance in T2D patients. 
Muscle in healthy individuals clears up the majority of glucose taken by peripheral 
tissues (muscle and peripheral glucose uptake) [11, 12]. However, this ability in T2D 
patients is severely impaired. In addition, hepatic glucose production (gluconeogenesis) 
in T2D-affected liver is also altered, and the organ overproduces glucose in the presence 
of insulin and hyperglycemia [12]. 
 
Excess glucose in plasma alone is known to cause several pathogenic effects. 
Hyperglycemia was first shown to damage β-cells in 1940 [13]. Other known 
pathological consequences associating to hyperglycemia include retinopathy, neuropathy, 
nephropathy, atherosclerosis [14-16], congenital birth defect [17], and fungal infection 
[18]. 
 
In addition to hyperglycermia and its pathogenic effects, multiple pathogenic 
consequences are related to T2D. These include higher blood fatty acid (FA) 
concentration, increased muscle triacylglycerol (TG, fat) content, and higher level of 
VLDL (very low density lipoprotein, known to increase cholesterol level in plasma) [19, 
20]. When these conditions persist for longer periods of time, individuals develop overt 
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T2D with increased production on ketone body. Prolonged circulation of ketone body 
would eventually cause ketosis and acidosis that induce coma and death. Individual 
factors such as high TG concentration and low HDL increase risks of the development of 
cardiovascular diseases. Thus, T2D is a metabolic syndrome that can induce complex 
pathogenic effects. 
 
 
 
Adipose Tissue and Adipocytes 
 
Obesity  is  one of the  major  risk  factors  relating  to  the  development  of  T2D [21]. In 
fact, more than 80% of the patients affected by type II diabetes are in the 
obese/overweight group [22]. In parallel to increased number of obese individuals, both 
adults and children, the number of individuals affected by T2D seems to keep increasing. 
However, it is important to note that the degree of insulin resistance is not much different 
among  normal/lean weight T2D patients and obese/overweight patients [11]. 
 
Adipose tissue is the largest reservoir of energy as the form of fat in mammalian body. 
Since obesity is one of the major contributors of the development of T2D, adipose tissue 
must be the one of key organs participating in the development of T2D.  
 
As individuals get obese, the adipose tissue often displays changes including sizes of 
adipocytes and altered metabolic activities, and the changes are particularly significant in 
the adipose tissue associated with internal organs. Obesity is also considered as an 
inflammatory condition of adipose tissue because of the increased entry and 
accumulation of macrophages in adipose tissue. These changes seem to deteriorate proper 
functions of the adipose tissue and increase the risks of cardiovascular disease and insulin 
resistance. On the other hand, fatless mice are also reported to be extremely susceptible to 
insulin resistance, hyperglycemia, fatty liver, and higher concentrations of TG and FA in 
circulation. Transplant and regeneration of adipose tissue into these fatless mice reversed 
those metabolic disorders, indicating an important metabolic role of adipose tissue [23, 
24].  
 
This tissue consists of several cell types including adipocytes (fat cells), macrophages, 
stromal cells, blood cells, and endothelial cells. There are two types of adipose tissue: 
brown and white adipose tissue. Brown adipose tissue is capable of thermogenesis, and 
adipocytes in brown adipose tissue contain a higher number of mitochondria. White 
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adipose tissue occupies the majority of whole adipose tissue mass in the body and play 
roles in whole body energy homeostasis by equilibrating lipid catabolism and lipid 
synthesis. Adipocytes in white adipose tissue can storing large amount of FAs as TG and 
can expand their sizes around 25 to 200 um in diameter depending on the volume of 
stored lipids (mainly TG) [25], and they serve as a major energy storage place in the 
body. Also, adipocytes can carry out “futile cycle”, in which they re-esterify (re-
incorporate) FAs generated from lipolysis of stored TGs into newly synthesized TGs, 
depending on physiological needs. 
 
In human adipocytes, at least 30% of FAs can be re-esterified into TG [26]. This ability 
indicates adipocytes’ dynamic regulation of lipolysis and FA re-esterfication to release 
adequate an amount of FA to plasma. Besides this lipid buffering function, adipocytes 
function as an endocrine organ and communicate with other organs by releasing peptide 
hormones such as resistin, leptin, and adiponectin in addition to adipokines including 
TNF-α and IL-6. These adipose tissue derived molecules are involved in several 
important physiological processes such as endocrine function (leptin, growth factors) 
[27], immune-inflammatory reactions (TNFs, IL-6) [28], metabolic processes (NEFA, 
adiponectin, resistin) [29-31], and cardiovascular functions (NEFA, PAI-1) [32, 33]. 
Therefore, nowadays adipose tissue has gained recognition as not only the energy storage 
site or connective tissue but also the metabolically active organ which plays important 
physiological functions. 
 
 
 
Fatty Acid Toxicity 
 
One of the adipose-related factors that appears to have important physiological roles in 
type II diabetes is plasma free FAs (non-esterified fatty acids, NEFAs), which can be 
generated either from food intake or lipolysis. Both normal/lean weight and obese T2D 
patients display prolonged elevation of NEFA level in plasma [19].  
 
Normally NEFA level increases after meals and is either used as energy or esterified into 
TG in adipocytes depending on physiological requirements. NEFA is acutely used as an 
energy source and facilitates insulin release from pancreatic β-cells [34, 35]. However, if 
elevated levels of NEFA chronically persist, it impairs insulin release from β-cells 
thereby worsening insulin resistance. Elevated levels of NEFA also interfere with glucose 
utilization in muscle and liver besides the reduction in β-cell insulin release. Also the 
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condition appeared to be sufficient to cause insulin resistance and pro-inflammatory 
response in liver [36, 37]. Moreover, it impairs hepatic glucose production 
(gluconeogenesis) and muscle glucose uptake causing hyperglycemia. Lowering NEFA 
concentration in type II diabetes patients has been shown to improve insulin sensitivity 
on these affected tissues thereby lowering hyperglycemia [38-40]. Thus NEFA is a key 
contributor to insulin resistance and T2D. The capacity of adipocytes to store large 
amount of lipids and buffer FA flux, gives the adipose tissue a unique ability of 
protecting other organs and tissues from NEFA. This FA absorbing ability is often 
impaired in malfunctioning adipocytes, which display larger cell sizes compared to 
healthy ones. It has been also indicated that the number of adipocytes is not proportional 
to the degree of obesity but that the adipocyte size is probably the problem [3]. Therefore 
adipocytes’ FA incorporating capacity is likely the one possible explanation why obesity 
is the risk factor of the development of T2D. 
 
 
 
The Origin of NEFA: Synthesis and Hydrolysis of Triglycerides 
 
The concentration of NEFA in blood is subjected to rapid variations associated to the 
ingestion of food and the nature of the food ingested. However, aside from these factors, 
the average NEFA concentration in plasma is mostly determined by the ratio between the 
adipose tissue output and uptake of NEFA. Thus, a proper balance between the rates of 
synthesis and degradation of TG in adipose tissue appears as major determinant of the 
probability to develop T2D. 
 
The rates of TG synthesis and degradation are hormonally controlled. Among the 
hormones insulin, glucagon and nor-epinephrine play major roles [41, 42]. However, 
several other factors and hormones influence the rates of TG synthesis and hydrolysis. 
Among these are the concentration of glucose [43], tumor necrosis factor NF-kappa beta 
(NF-kβ) [44], adiponectin [45], HGH, and so on. The rate of TG hydrolysis is determined 
by the activity of two lipases, hormone sensitive lipase (HSL) and adipose TG lipase 
(ATGL) [46, 47]. These enzymes are directly (HSL) or indirectly (ATGL) regulated by 
reactions of phosphorylation/dephosphorylation catalyzed by kinases. A major kinase 
involved in HSL regulation is cAMP-acitivated protein kinase (PKA) [48], which is 
activated at low insulin levels and the presence of β-adreneric receptor agonist such as 
isoproterenol.  ATGL is regulated by CGI-58 [49]. Apart from the regulation by kinases 
the expression levels of ATGL appear to play a major role in the rate of lipolysis.  
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The rate of synthesis of TG can be regulated at several enzymatic steps involved in the 
conversion of FA into TG. One of the main control points of the rate of TG synthesis 
could reside in the availability of G3P [50]. Because under most physiological conditions 
adipocytes do not express glycerol kinase, the capability of adipose tissue to 
phosphorylate glycerol and re-use it for the synthesis of TG is negligible [51]. For this 
reason, most of the glycerol produced during lipolysis is released from adipose tissue and  
re-utilized in the liver, which can phosphorylate and incorporate it into the glycolytic or 
gluconeogenic pathways.  
 
It has been suggested that when insulin is not sufficient (fasting) or when the adipose 
tissue presents insulin resistance the availability of glucose is limited and the synthesis of 
G3P from glucose would not be sufficient to support the required synthesis of TG… It 
has been proposed that under these conditions glyceroneogenesis would supply the 
equivalents of G3P required. Investigation of the relative contributions of glycolysis and 
glyceroneogenesis to the synthesis of glyceride-glycerol (Glycerol constituting the 
backbone of TG) is a major goal of our work.  
 
 
 
Metabolic Effects of Rosiglitazone, a PPAR-γ Activator, Commonly Used to Treat 
T2D: Role of Glyceroneogenesis and Glycerol Phosphorylation 
 
Since controlled diet and regular exercise are insufficient to improve insulin resistance 
and hyperglycemia [52], pharmacological strategies play important roles in the treatment 
of T2D. The anti-diabetic drugs released to the market in past few decades have one or 
more of following effects: (a) stimulate insulin release from pancreas [53, 54], (b) 
improve insulin sensitivity in peripheral tissues (liver, muscle, and adipose tissue) [55, 
56], (c) prevent glucose uptake from intestine [57], and (d) inhibit hepatic glucose 
production [58].  Several combinations of these agents are used to maximize therapeutic 
effects to improve diabetic conditions.                         
 
Rosiglitazone (RGZ, Avandia) is a hypoglycemic drug used for the treatment of T2D and 
it is a member of the thiazolidinediones (TZDs) class of chemicals. RGZ improves 
insulin sensitivity of peripheral tissues to enhance glucose disposal. TZDs are agonists of 
peroxiosome proliferator-activated receptor-γ (PPAR-γ), a member of nuclear receptor 
transcription factors that is primary expressed in adipocytes [59]. Normally PPAR-γ 
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expression is induced during differentiation of pre-adipocytes into mature adipocytes 
(adipogenesis) [60], and individuals with the dominant-negative mutation in PPAR-γ 
expression appear to be severely insulin resistant and lipodystrophyic [61]. 
 
PPAR-γ activation by TZDs in mouse adipocytes has been reported to up-regulate 
expression of several adipose genes encoding proteins involved in energy metabolism, 
including proteins related to FA transport, oxidative phosphorylation, lipid catabolism 
and TCA cycle [62]. These observations imply that the primary target of TZDs is 
adipocytes/adipose tissue. However, insulin-sensitizing effects on other peripheral tissues 
such as liver and muscles are also observed. For example, muscle cells barely express 
PPAR-γ, but RGZ promotes a major improvement on insulin sensitivity and glucose 
disposal on skeletal muscle [63]. This action of the drug is thought to be mediated in part 
by the effect of RGZ on the concentration of circulating NEFA. 
 
PPAR-γ works with several different transcriptional factors as a co-activator or co-
repressor of transcriptions of various genes. RGZ has shown to have insulin-sensitizing 
and glucose lowering effects on patients with T2D.  
 
 
 
 
 
Glyceroneogenesis 
 
Glyceroneogenesis is a truncated version of gluconeogenesis (Fig.1) and is a largely 
unexplored metabolic pathway [64]. In glyceroneogenesis, non-glucose precursors such 
as lactate, pyruvate, and alanine are used to produce glycerol 3-phosphate (G3P) [50]. It 
has been shown that in lipolytic conditions, such as fasting, pyruvate carobxylase (PC) 
and cytosolic phosphoenolpyruvate carboxykinase C (PEPCK-C) are up-regulated in 
adipose tissue.  PEPCK-C converts oxaloacetate generated from pyruvate into 
phosphoenolpyruvate, and subsequent reactions produce G3P. The rate of synthesis of 
G3P in adipocytes is thought to be important in determining the capacity of adipose tissue 
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to esterify FA and, ultimately, the rate of NEFA clearance from plasma. Enhanced G3P 
production in adipocytes could facilitate the rate of FA esterification promoting a 
decrease of NEFA in plasma and, thus, improving insulin sensitivity of peripheral tissues.  
 
PEPCK-C activity is observed in several different tissues including kidney, liver, and 
muscle, but the enzyme is barely active in adipocytes. Studies have shown that RGZ 
treatments up-regulate PEPCK-C mRNA expression and increase the enzymatic activity 
in mouse and human adipose tissues in fasting lipolytic condition [65]. The studies also 
reported that increased incorporation of radioactivity (cpm) of [14C1]-pyruvate into lipid 
upon activation of PEPCK-C activity in RGZ-treated adipocytes. Thus, some studies 
have proposed that RGZ improves the health of type II diabetic patients by promoting 
glyceroneogenesis in adipocytes [66-69]. 
 
However, transgenic mice overexpressing PEPCK-C in adipose tissue appeared to be 
more susceptible to diet induced insulin resistance and weight gain, and showed no 
changes in NEFA concentration in plasma [70]. This observation did not support the 
beneficial effect of glyceroneogenesis and/or a key role of PEPCK in controlling the rate 
of glyceroneogenesis.  
   
A full understanding of the metabolic effects of RGZ in adipose tissue is lacking. 
Therefore one of the main goals of our studies is to gain insights into the metabolic 
consequences of RGZ treatment (Chapters III & IV).   
 
 
Glycerol Kinase 
 
An alternative mechanism to synthesize G3P is by direct phosphorylation of glycerol in a 
reaction involving glycerol kinase (GK). This enzyme is expressed in several tissues but 
it is specifically active in liver and absent in adipose tissue (Fig. 1). A relatively recent 
study reported that induction of GK expression in response to TZD treatment in human 
and mouse adipose tissue [71].  This is surprising since GK expression was thought to be 
absent in white adipose tissue. Moreover, the study reported that RGZ enhances GK 
activity and increases the incorporation of [14C]-glycerol into lipids. Therefore, it was 
proposed that GK expression could be a key contributor to the anti-diabetic effects of 
TZD’s. On the other hand, a follow up study failed to replicate the findings and could not 
demonstrate changes in GK expression upon RGZ treatment in mouse and human 
adipocytes [72]. Moreover, as in the case of glyceroneogenesis, the study supporting a 
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role of GK in TG synthesis did not provide quantitative estimates of the rates of 
incorporation of glycerol into lipids. 
 
 
 
 
 
 
Figure 1: Metabolic routes involved in the synthesis of glyceride-glycerol in 
adipocytes. The figure illustrates an abbreviated version of the metabolic 
pathways involved in the synthesis of glyceride-glycerol (G-G) that could 
contribute FA lowering action of RGZ in adipocytes.  Glycerol 3-phosphate (G3P, 
which eventually serves as G-G of TG) synthesis though glyceroneogenesis 
requires up-regulation of phosphoenolpyruvate carboxylase-C (PEPCK) and 
pyruvate carboxylase (PC). Glycerol kinase (GK) is required for the 
phosphorylation of glycerol which can be generated from lipolysis or taken up 
from plasma. Lipolysis and FA re-esterification are also emphasized. 
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Research Objectives and Significance 
 
This project was based on the notion that previous studies have not addressed in a 
quantitative fashion the metabolism of glucose and pyruvate in adipocytes. We have 
hypothesized that it is possible to determine the contribution of glucose and pyruvate 
carbons to the synthesis of the glycerol backbone of TG. If this is possible, then, we 
could also gain a better understandings of the mechanisms by which TZDs, and RGZ in 
particular, have an anti-diabetic effect.  In this context we have pursued the following 
specific aims: 
 
• Study the metabolism of glucose in adipocytes and determine the rate of 
glyceride-glycerol (G-G) synthesis from glucose under different metabolic 
conditions (Chapter II). 
 
• Investigate some of the possible causes of the metabolic changes induced by RGZ 
(Chapter III). 
 
• Investigate the changes induced by RGZ on the metabolisms of glucose and 
triglycerides in adipocytes (Chapter IV).  
 
• Estimate the contribution of pyruvate to the rate of synthesis of G-G in adipocytes 
under different physiological conditions (Chapter IV). 
 
• Determine the overall contribution of glyceroneogenesis to the synthesis of 
glyceride-glycerol in adipocytes under different physiological conditions. 
Determine the effect of RGZ treatment on the rate of glyceroneogenesis and its 
overall contribution to the synthesis of glyceride-glycerol (Chapter IV). 
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Given the major role of adipose tissue in the development of diabetes type II, it is 
important to improve our understanding of the metabolism of glucose and triglycerides in 
adipocytes. Although many studies have previously addressed several aspects of the 
metabolism of TG and glucose, the present studies intend to fill some gaps that are 
considered of significance for the understanding of adipose tissue physiology and its role 
in the development of diabetes. Moreover, a full understanding of the metabolic effects of 
RGZ in adipose tissue is lacking. One of the main goals of our studies is to gain insights 
into the metabolic consequences of RGZ treatment (Chapters III & IV).  By gaining 
knowledge on the effects of a drug that is beneficial to the treatment of diabetes, we may 
learn something significant for the understanding of the development and/or prevention 
of T2D.  
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CHAPTER II 
 
 
 
 
ESTIMATION OF METABOLISM OF GLUCOSE AND TG IN ADIPOCYTES 
 
 
 
Introduction 
 
Adipose tissue is a very active organ in the regulation of the availability of substrates for 
energy production. TG is the major lipid component of adipocytes and the source of FA 
to other tissues when the supply of glucose is limited. Since an excess of FA has 
pathogenic effects on tissues and organs, the rate of FA output must be tightly regulated. 
Regulation of the synthesis of glyceride-glycerol (G-G) in adipocytes is essential to 
maintain proper NEFA concentration in plasma.  
 
In this chapter we estimated the rates of utilization of glucose, and the fate of glucose 
carbons, in adipocytes in the presence and in the absence of insulin. We also describe a 
method that allows the estimation of the rate of incorporation of glucose carbons into the 
glycerol backbone of TG.  
 
 
 
Experimental Procedures 
 
Materials. 3T3L-1 mouse cell line was obtained from American Type Cell Culture 
(Manassas, VA). Fatty acid free bovine serum albumin (FA-free BSA), isobutyl methyl 
xanthine (IBMX), dexamethasone  (DEX),  trypsin,  biotin,  sodium  pyruvate,  insulin,  
streptomycin  and  penicillin  were  purchased  from Sigma Chemicals Co.  (St.  Louis, 
MO).  Fetal bovine serum (FBS) and calf bovine serum (CBS) were obtained from 
Hyclone (Logan, UT).   
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Dulbecco’s modified Eagle’s medium (DMEM) was purchased from Cellgro Mediatech, 
Inc (Herndon, VA). Rosiglitazone (RGZ) and [U-14C]-glucose were purchased from 
American Radiolabeled Chemicals (St. Louis, MO).   
 
 
Cell culture and differentiation. To obtain a homogeneously differentiated culture of 
adipocytes we used an  experimental  procedure  as  described  by  Rubin  et  al.[73]  
3T3L-1 pre-adipocytes were maintained at 37°C in 8% CO2 atmosphere in high glucose 
DMEM supplemented with 10% CBS and 0.01% antibiotics.  Upon  confluence,  
differentiation  from  preadipocytes  into  mature  adipocytes  was induced by addition of  
medium containing  DMEM/10% FBS,  IBMX (111 µg/ml), DEX  (0.46 µg/ml), and  
insulin  (1.5 µg/ml)  supplemented  with  biotin  (4 µg/ml)  and  sodium  pyruvate  (100 
µg/ml).  After 72 hours, the cells were incubated in DMEM/10% FBS containing insulin, 
biotin, and sodium pyruvate for another 72 hours. Once differentiation was completed, 
the cells were maintained in the DMEM/10% FBS medium.  All metabolic studies were 
performed in fully differentiated cells.  This is achieved between 9 and 15 days after 
initiation of the differentiation.   
  
 
Metabolism of glucose and lipids in adipocytes. Mature adipocytes were incubated in the 
DMEM/10% FBS medium. Cells were briefly  washed  by  incubating  them  in  Krebs  
Ringer  Bicarbonate  (KRBH)  medium  containing  6mM glucose  and  0.12%  FA-free  
BSA. The  wash  medium  was  replaced  with  the  KRBH  experimental medium  
containing  either  insulin  (1µg/ml),  isoproterenol  (1µg/ml),  or  DMSO  (control)  in  
addition  to 6.0mM  glucose  and  0.12%  albumin.  Immediatly  after  replacing  the  
wash  medium  with  experimental medium,  [U-14C]-glucose  (1.5 to 6µCi/well, 
depending on plate size)  was  added.  The incubation in the presence of radiolabeled 
glucose proceeded for 1h. After this time, the medium was removed and placed on ice 
and the cells were homogenized in 150 mM Tris buffer containing 50 mM sodium 
chloride (pH 7.5).   
 
 
Medium analysis. The levels of fatty acids, glycerol, glucose and lactate in the incubation 
medium were determined by spectrophotometric methods. NEFA and glycerol 
concentration were measured with the enzyme coupled colorimetric   kits   (NEFA:   
NEFA-C;   Wako,   Richmond,   VA,   glycerol:   Infinity Triglyceride; Sigma, St. 
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Louise, MO). Lactate was quantified based on its oxidation by NAD+ catalyzed by LDH 
[74].  
 
  
Lipid analysis. Total lipids were extracted from cell homogenates using the Folch method 
[75]. Lipid classes, phospholipid  (PL),  diglyceride  (DG),  FA,  and  TG,  were  
separated  by  thin layer chromatography (TLC) on silica gel 60 Å plate (Whatman, 
Maidstone, UK) using hexane: ethyl ether: formic acid (70:30:3 by vol) as developing 
solvent.[76] Lipid spots were visualized with iodine vapor, and the radioactivity 
associated to each spot was determined by scintillation counting.   
  
TG hydrolysis was performed to determine percentages of radioactivity incorporated into 
the glyceride (G-G) backbone and fatty acid chains of TG. Triglyceride spots were 
scrapped from the TLC plates and the lipid extracted from the silica using Folch solvent. 
TG extracts were dried and hydrolyzed by incubation with 0.5 M potassium hydroxide in 
ethanol at 65 °C for 1 hour. The solution was acidified with 12 M hydrochloric  acid,  and  
glycerol  and  fatty  acid  were  separated  based  on  their  solubility  in  water  and Folch  
solvent  (chloroform:methanol  =  1:1 by vol). Radioactivity in glycerol and fatty acids 
was determined by scintillation counting.  The percentages  of  radioactivity  in  total  
lipid  extract,  different lipid  types,  and  glyceride-glycerol (G-G)  backbone  and  FA  
chain  of  TG  were  used  to  determine  rates  of  glucose conversion into lipids.   
 
 
Glycogen content. Cellular glycogen content was assayed using the samples which were 
frozen immediately after homogenization. Briefly, cell homogenate was boiled and 
centrifuged to remove protein pellet. Supernatant was treated with amylo-glucosidase in 
0.8M acetate buffer (pH. 4.5) to digest glycogen to glucose. Glucose content was 
measured using HK glucose kit (Sigma-Aldrich, St. Louise, MO) based on oxidation of 
NADH. 
 
 
Intracellular specific activity of glucose. The specific activity of lactate (SAlac, 
cpm/nmol) derived from [U-14C]-glucose was estimated to determine the intracellular 
specific activity of glucose (SAglu). The  amount  of  lactate  produced  (1h)  was  
calculated  from  the  difference  between  initial and  final concentrations of lactate in the 
cell culture medium. The radioactivity associated with lactate in the cell culture  medium  
was  determined  after  separation  of  the  lactate  by  TLC.  Briefly,  5  µl  of  medium  
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was loaded onto a silica gel 60 Å TLC plate (Whatman, Maidstone, England), and 
developed with a solvent mixture containing methanol: water: ammonium hydroxide 
(60:39:1=v:v:v). The spots from lactate and other  radiolabeled  compounds  were  
visualized  by  autoradiography  with  Fuji  RX  film  (Fuji  Medical Systems,  Stevenson  
Court,  IL)  after  12  hours  to  1  week  of  exposure  time.  The spot corresponding to 
lactate was scraped, and radioactivity was counted using a scintillation counter.   
 
  
Calculations. Rates of glyceride-glycerol (G-G) backbone synthesis (total TG synthesis = 
de novo TG synthesis + TG re-esterification)  from  glucose  were  calculated  from  the  
radioactivity  incorporated  into  lipids  and  the specific activity of glucose. The rates of 
incorporation of glucose carbons into TG, G-G and fatty acids (FA-chains), were 
calculated from the distribution of radioactivity (percentages) among lipid species, and 
between the fatty acyl chains and G-G backbone of TG.   
 
 
Other methods. The protein concentration in cell homogenates was determined 
spectrophotometrically in the presence of 10% SDS [77].  
 
 
 
 
Results 
 
 
Utilization of glucose carbons for lipid synthesis. To study the metabolism of glucose 
and lipid, adipocytes were incubated in KRBH medium (9.5 mM glucose/ 0.12 % BSA in 
KRBH) with [U-14C]-glucose. Three different metabolic conditions were generated and 
analyzed by incubating the cells in KRBH medium containing: a) Insulin, to induce a low 
lipolytic state and promote lipogenesis; b) Isoproterenol, which stimulates lipolysis and; 
c) DMSO (control medium), which is the solvent used to dissolve isoproterenol. Exactly 
one hour after the addition of radioactive glucose, medium in each well was separated 
and cells were homogenized and frozen. The effect of the hormones on the metabolic 
state of adipocytes was confirmed by measuring the levels of certain medium metabolic 
parameters. As shown in Table I, insulin promotes a decrease in the release of glycerol to 
the medium, indicating a decrease in the rate of lipolysis (TG hydrolysis). As expected, 
isoproterenol significantly enhanced the lipolytic rate of adipocytes. These effects are 
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also reflected in the levels of NEFA. The increase in lactate levels observed with both 
insulin and isoproterenol indicated that these hormones enhance the rate of glycolysis. 
 
 
Table I: Effects of insulin and isoproterenol on the metabolism of adipocytes. 
nmol/mg.h 
  Control Insulin Isoproterenol 
Glycerol  13.38  ± 1.9 7.23  ± 0.5 92.15  ±  1.8 
Lactate  182.34  ± 19.1 258.04  ± 7.2 421.87  ±  26.7 
NEFA  2.38  ± 0.5 0.13  ± 0.04 11.95  ± 1.16 
 
Glycerol, lactate, and NEFA released into the experimental medium were spectrophotometrically 
measured after the 1 hour incubation with DMSO (control), insulin, and isoproterenol in KRBH 
medium. The initial components of the experimental medium besides the corresponding hormones 
included 9.5 mM glucose, 0.12 % FA-free BSA, and KRBH. The data shown represent the means 
(nmol/mg.h) ± SD (n=3). 
 
 
The incorporation of glucose carbons into lipids and the distribution of radioactivity 
among cellular lipid classes were determined in the lipids extracted from cell 
homogenates. The amount of radioactivity incorporated in total lipids was highest in the 
cells incubated with insulin. In control and insulin containing media most of the 
radioactive glucose was incorporated into PL (~30 %) and TG (~60 %). However, about 
80% of the [14C]-glucose incorporated into lipids was found in TG when the cells were 
incubated in the medium containing isoproterenol. This result suggests a relationship 
between TG synthesis and hydrolysis and the rate of glucose metabolism in 3T3L-1 
adipocytes (Fig. 2A and B).  
 
To calculate the rate of glucose carbon utilization for the synthesis of glyceride-glycerol 
(glycerol backbone), TG isolated by TLC were subjected to alkaline hydrolysis to cleave 
FA chains from a glyceride backbone. Glycerol and FA were separated based on their 
solubility in organic and aqueous solvents. The fraction of [14C]-glucose used for the 
synthesis of FA and glyceride-glycerol were calculated from the radioactivity associated 
with FA and glycerol. The Figure 2C shows that in the presence of insulin a large 
proportion of the glucose carbons incorporated into lipids was used for fatty acid 
synthesis (~ 65%), whereas ~35% is used for the synthesis of the glyceride backbone of 
TG. Conversely, under lipolytic conditions (isoproterenol) ~90 % of [14C]-glucose 
carbons are used for the synthesis of glyceride backbone.  
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Figure 2: Incorporation of glucose carbons into the lipids of adipocytes. A) 
Percent of radiolabelled glucose incorporated into total lipids of adipocytes 
incubated with hormones and [U-14C]-glucose; B) Relative distribution of glucose 
carbons among lipid classes (PL: phospholipids, DG: diacylglycerol, FA: fatty 
acids, and TG: triglyceride); C) Distribution of radiolabeled carbons between the 
FA chain and glycerol (G-G) backbone of TG. All data is expressed as mean ± SD 
(n=3) 
 
 
 
Actual rates of glucose conversion into lipids. In the previous sections, we obtained 
percentages of radioactivity incorporated into the lipid fractions under different 
conditions.  These numbers are useful but do not provide all the information needed to 
calculate the rate of utilization of glucose carbons for the synthesis of glyceride-glycerol 
or fatty acids. In order to determine these rates, it was necessary to estimate the specific 
activity of glucose inside adipocytes. Since adipocytes produce large amounts of lactate 
(Table I and Fig. 3A), which is expected to be derived mostly from the metabolism of 
glucose, an estimate of the glucose specific activity inside of cells was calculated by 
determining the specific activity of lactate released into medium. Due to the difference in 
the rates of glycogenolysis (Fig. 3B), the specific activity of glucose was dependent on 
the cell treatment and significantly different among the conditions of the incubation. The 
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specific activity of glucose in cells incubated with isoproterenol was lower compared to 
that of control and insulin treated cells. 
 
The estimated rates of glucose conversion for the synthesis of lipids showed that, 
compared to control and insulin treated cells, adipocytes incubated with isoproterenol use 
more glucose to make both total lipids and TG (Fig. 3C and D). The rates of TG synthesis 
were estimated from the specific activity of glucose, the radioactivity in total lipid 
extracts, and the fraction of radioactivity in TG and in the glyceride backbone of TG (Fig. 
3F). 
 
 
 
 
Figure 3: Rates of glucose utilization for lipid synthesis. A) Two major medium 
metabolites, lactate and glucose, were separated using aqueous-base TLC, and visualized 
by autoradiography. Radioactivity in each spot was counted to determine the specific 
activity of lactate (cpm/nmol) with the amount of lactate present in the medium; B) 
Intracellular glycogen content was estimated to determine the effects of hormones; C) 
Rate of incorporation of glucose carbons in total lipids; D) into TG and F) into the 
glycerol backbone and fatty acid moieties of TG.. These rates were calculated using the 
specific activity of glucose inside the cells.  All data are shown as mean ± SD (n=3). 
 
 
 19
 
Summary 
 
In this chapter, we have shown results, that as shown by previous studies in adipocytes, 
were expected. For instance we have shown that incubation with insulin promotes a low 
lipolytic state and accordingly adipocytes release less glycerol and NEFA. Similarly, we 
have shown that the cells release large amount of glycerol and NEFA in the presence of 
isoproterenol, which is a well known lipolytic agent (Table I). These results have been 
shown in several previously reported studies [78, 79]. 
 
We have also shown that the utilization of glucose increases significantly not only in the 
presence of insulin, but also in its absence when the cells are exposed to isoproterenol. 
The stimulation of glucose utilization when lipolysis is stimulated has been previously 
demonstrated [80]. However, there is a common belief that cells cannot use much glucose 
in the absence of insulin. In this sense reiterating old studies that are often forgotten was 
necessary. The studies included in this chapter were also necessary for us to find out how 
much we could do with the small amounts of material available from adipocytes grown in 
tissue culture plates.  
 
The most important finding of the studies shown is that it is possible to estimate the 
intracellular specific activity of radiolabeled glucose.  This is an original aspect of the 
studies and it is important because it allows estimating the rates of utilization of glucose 
carbons for the synthesis of fatty acids and glyceride-glycerol.  Here, we showed that an 
increase in the lipolytic rate is accompanied by a concomitant increase in the 
incorporation of glucose carbons in the glycerol backbone of TG. This result shows that 
even in the absence of insulin, adipocytes re-esterify most of the fatty acids produced by 
the increased lipolytic rate, and this generates a demand for glucose carbons to produce 
glycerol-3-phosphate (G3P).  In the presence of insulin, the incorporated glucose is 
utilized mostly for the synthesis of fatty acids.  
 
The studies shown in this chapter constituted the basis of the studies directed to 
understand the effects of RGZ in the metabolism of glucose and TG in adipocytes that are 
presented in the following chapters. 
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CHAPTER III 
 
 
 
 
CHANGES IN THE METABOLISM OF GLUCOSE AND TG IN ADIPOCTE 
TREATED WITH ROSIGLITAZONE 
 
 
 
 
 
Introduction 
 
RGZ improves insulin sensitivity of the body and decreases hyperglycermia and NEFA in 
T2D patients. The beneficial effects of RGZ translate in an enhanced glucose disposal in 
muscle and suppressed hepatic glucose production in liver. Since the target of RGZ, 
PPAR-γ, is mainly expressed in adipose tissue, the origin of anti-diabetic effects of this 
drug are thought arise from the metabolic changes induced in adipose tissue. The 
purposes of the studies presented in this chapter were to: 
 
1. Investigate the changes induced by RGZ on the metabolisms of glucose and 
triglycerides in adipocytes. These studies were directed to learn about the role of 
adipocytes in the glucose and NEFA lowering effects of RGZ. We investigated 
the effects of RGZ on: a) the rate of utilization of glucose; b) the rate of synthesis 
and hydrolysis of TG. 
 
2. Investigate some of the possible biochemical causes of the metabolic changes 
induced by RGZ. We investigated changes in the expression and/or activity of 
certain enzymes involved in the metabolism of glucose and triglycerides. 
 
. 
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Experimental Procedures 
 
 
Metabolism of glucose and lipids in adipocytes. Mature adipocytes were incubated in the 
DMEM/10% FBS medium containing either ethanol (control) or 500 nM RGZ for 24 
hours. After 24 hours, cells were briefly  washed  by  incubating  them  in  KRBH  
medium  containing  6mM glucose, 2mM lactate,  and  0.12%  FA-free  BSA. The  wash  
medium  was  replaced  with  the  KRBH  experimental medium  containing  either  
insulin (1µg/ml), isoproterenol (1µg/ml),  or DMSO  (control)  in  addition  to 6.0mM  
glucose, 2mM lactate, and 0.12% albumin. The incubation in the presence of radiolabeled 
glucose proceeded for 1h. After this time, the medium was removed and placed on ice 
and the cells were homogenized in 150mM Tris buffer containing 50mM sodium chloride 
(pH 7.5). 
 
Enzyme Activity Assay. Activities of hexokinase (HK) [81], glycerol 3-phosphate 
dehydrogenase (GPDH) [82], lactate dehydrogenase (LDH) [83], and glyceraldehydes 3-
phosphate dehydrogenase (GAPDH)  [84] were measured spectrophotometrically based 
on the oxidation/reduction of NAD+/NADH as previously described. Glycerol kinase 
(GK) activity was determined spectrophotometrically using a colorimetric assay [85, 86].  
 
Transcriptional changes in glycerol kinase expression: The transcriptional levels of GK 
were determined by reverse transcription PCR. Total RNA was extracted from 3T3L-1 
adipocytes incubated in the medium containing either 500nM RGZ or ethanol (control) 
for 24 hours with Trizol reagent (Invitrogen, Carlsbad, CA) according to the 
manufacturer’s instruction. One step RT-PCR was performed to the total RNAs for GyK, 
and 18SrRNA (18R) with Qiagen one-step RT-PCR kit (Qiagen, Valencia, CA). 
Integrated Density Values (IDVs) for GK was normalized by IDV of 18R using 
AlphaEaseFC program (Alpha Innotech Corp, San Leandro, CA). Mouse primers used 
were following: GK sense 5’-GCTGTAATCCGCTGGCTAAG-3’, and antisense 5’-
GTGCAGCAAAAGCGATATGA-3’; 18R sense 5’-TACCACATCCAAGGAAGGCA-
GCA-3’, and antisense 5’-TGGAATTACCGCGGCTGCTGGCA-3’. All primers were 
designed and obtained from Integrated DNA Technologies, Inc (Coralville, IA).  
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Western Blot. Western blot analysis was performed using whole cell homogenate of the 
cells treated with or without RGZ and the hormones. Aliquots of the cell homogenates 
containing identical amounts of protein (15 µg) were separated by SDS-PAGE in 4-20% 
gels and blotted onto nitrocellulose membranes. Bound antibodies were detected using 
the enhanced chemiluminiscence assay system (Pierce Chemicals, TX). The photographic 
films were scanned and the intensity of the spots determined by densitometry using the 
AlphaEaseFC program (Alpha Innotech Corp, San Leandro, CA). 
 
Primary antibodies against mouse adipose triglyceride lipase (ATGL) and hormone 
sensitive lipase (HSL) were purchased from Cell Signaling Technology (Danvers, MA). 
Goat anti-mouse GAPDH primary antibody was obtained from Chemicon International, 
CA.  
 
 
Statistics. The statistical significance between untreated and RGZ treated samples was 
determined with the Student’s t-test using Instat software (GraphPad Software Inc, La 
Jolla, CA) 
 
 
Other Methods. Cell culture, glycogen assay, and analysis of lipid and metabolites were 
performed using the procedures described in Chapter II. Same materials as in chapter II 
were used for the experiments (if not mentioned). 
 
 
 
 
Results 
 
 
Effect of RGZ treatment on fatty acid metabolism. We first tested the concentration of 
RGZ and time of incubation needed to observe metabolic changes in adipocytes. For this 
purpose we monitored the cellular output of NEFA. This study showed that, 
independently of the presence or absence of insulin, a maxium effect is reached at a 
concentration of RGZ of about 500nM (Fig. 4A). This concentration is similar to the 
average concentration found in plasma of patients treated with normal doses of RGZ. 
Several times of incubation were tested and it was found that after 16h of incubation the 
effects leveled off (Fig. 4B). Therefore, all the following experients were carried out with 
pre-incubation the cells with 500nM RGZ for 24h. After this treatment, the cells were  
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incubated in KRBH medium containing either insulin (1µg/ml), isoproterenol (1µg/ml), 
or DMSO (control) in addition to 6.0mM glucose, 2mM lactate, and 0.12% albumin (FA-
free BSA). 
 
 
 
 
Figure 4. Effects of RGZ concentration and incubation time on NEFA release 
from adipocytes. Adipocytes were incubated with different concentration of RGZ 
for 24h, and NEFA release was measured (A). The effect of 500nM RGZ on 
NEFA release from adipocytes in the presence or absence of hormones was 
determined (B). All data represent mean ± SD (n=3, ●: control, ■:isoproterenol, 
▲: insulin). 
 
 
 
 
In order to investigate the effect of RGZ in TG metabolism we determined the cellular 
ouputs of NEFA and glycerol, as well as the cellular content of FFA and ability of the 
cells to metabolize externally added FFA. The effects of RGZ were determined under 
three lipolytic conditions, low (insulin), intermediate (no hormones added) and high 
(isoproterenol). Table II shows the average data of lipoylysis (glycerol release) and 
NEFA output from a single experiment. Figure 5A and 5B show the average changes (%) 
in NEFA and lipolysis from several experiments. Contrarily to the expected result, a 
decrease in lopolysis, treatment of adipocytes with RGZ promotes an increase in 
lipolysis. The results were somewhat surprising because simultaneously to the increase in 
lipolysis there is a decrease in the output of FA. 
   . 
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Table II. Glycerol and NEFA release in response to RGZ. 
 
Adipocytes were incubated with 500nM RGZ (+RGZ) or DMSO (-) prior to the experiment for 24h. Glycerol and 
NEFA released into the incubation medium were using colorimetric assay after 1h incubation time as described in the 
method section. Initial components of the medium consisted of 6mM glucose, 2mM lactate, 0.12% FA-free BSA, and 
KRBH besides hormones (insulin and isoproterenol). Adipocytes All data is expressed as rate (nmol/mg.h) ± SD 
(n=5-9, **: p<0.001 and ***: p<0.0001 for +RGZ groups compared to non-treated (-) samples ). 
 
 
 
 
 
 
 
Figure 5. Average NEFA reduction and increase in lipolysis in RGZ-treated 
adipocytes. Average changes (%) of the rates of NEFA release (A) and lipolysis 
(B) were calculated using data from several experiments. All data is shown as 
mean ± SD (3-4 experiment, n=12). 
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In addition to these results, the analysis of lipid contents in adipocytes showed no 
increase in the levels of intracellular NEFA and TG (Fig. 6A and B). These results 
suggested that the lower cellular output of NEFA was due to a RGZ promoted increase in 
the synthesis of TG (FA re-esterification), which exceeds the increase in lipolysis. To 
confirm this interpretation the ability of adipocytes to uptake externally added NEFA was 
determined by incubating the cells in the presence of BSA containing 1.6mM FA. As 
shown in Figure 6C, under the three experimental lipolytic conditions tested, RGZ 
effectively increases the ability of adipocytes to uptake and esterify FA. Overall, the 
studies of lipolysis, NEFA release and uptake, intracellular TG and NEFA content 
indicate that RGZ promotes an asymmetric up-regulation of two opposite processes, 
lipolysis and NEFA re-esterification. Thus, RGZ promotes a synthesis biased increase in 
the rate of the futile cycle constituted by the processes of synthesis and hydrolysis of TG. 
 
 
Figure 6. Effects of RGZ on intracellular FA, tissue TG, and NEFA absorption in 
adipocytes. Intracellular FA (A) and TG (B) were measured using cells incubated with 
different hormones for 1h after 24h RGZ treatment. NEFA uptake was studied in 
KRBH medium containing 1.6mM FA, 9mM glucose and 0.12% BSA after 1.5 hours 
of incubation time. The rate of NEFA absorption was calculated based on NEFA 
disappearance from the medium over time (C). Blank bars (□) indicate control (0h 
RGZ incubation) and filled bars (■) express RGZ-treated samples. All data show mean 
± SD (n=3 for A, n=12 for B, n=9 for C. *: p<0.05 and **: p<0.005.) 
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Effect of RGZ treatment on glucose metabolism. To learn about possible effects of RGZ 
on the metabolism of glucose, the consumption of glucose, the levels of intracellular 
glycogen and the levels of lactate in the experimental medium were determined. These 
determinations were performed in untreated and RGZ-treated cells before and after a 1 h 
incubation period in the experimental medium. The data from one representative 
experiment are shown in Table III. These data indicate that RGZ promotes a large 
increase in glucose consumption and lactate production. Average increases in glucose 
consumption in RGZ-treated cells were similar in the absence of hormones –control cells- 
(~65%) or in the presence of isoproterenol (~61%), and lower in the presence of insulin 
(~38%). On the other hand, the increases in glucose consumption were accompanied by 
proportional increases in lactate production (Table III).  
 
These results indicate that RGZ promotes an increase in the rate of glycolysis.  In 
addition to the increase in uptake of extracellular glucose, RGZ treatment also 
accelerated the breakdown of cellular glycogen (Fig. 7A & B). Therefore, we can 
conclude that RGZ does not promote accumulation of glucose, but rather it promotes a 
significant increase in glycolysis. Overall, these studies have shown that RGZ increases 
the rate of glucose utilization to fuel the promoted increase in the rate of the futile cycle 
of TG synthesis and hydrolysis.  
 
 
Table III. RGZ-induced changes in glycolysis 
 
Adipocytes were incubated with 500nM RGZ (+ RGZ) or DMSO (-) for 24 h prior to the in vitro experiment. 
Lactate released into and glucose consumed from the medium after 1 hour incubation were determined as 
described in methods. The initial medium contained 6mM glucose, 2mM lactate, 0.12% FA-free BSA, and KRBH 
besides hormones (insulin and isoproterenol). All rates are expressed as means ± SD (n=9-12, ***: p<0.0001 for 
+RGZ groups compared to non RGZ treated group in each lipolytic state).  
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Figure 7. Intracellular glycogen content in adipocytesis is altered by RGZ. 
Intracellular glycogen concentration was measured in the cells treated with and 
without 500nM RGZ for 24 hours (A). Average decrease in glycogen 
concentration was calculated (B). After the incubation with/without 500nM 
RGZ for 24h the cells were maintained in the medium containing 9.5mM 
glucose and 0.12% BSA. The empty bar (□) indicates control (oh incubation 
with RGZ) and the black bar (■) represent incubation with RGZ for 24h. Data 
is expressed as mean ± SD (n=3 for the determination of glycogen 
concentration. 3-4 sets of experiments were used to estimate average reduction 
in response to RGZ. **: p<0.005).  
 
 
 
Effect of RGZ on the activities and expression of some enzymes involved in TG and 
glucose metabolism. Since RGZ is an activator of the transcription factor PPARγ, it was 
reasonable to expect that changes in the expression of some enzymes were underlying the 
changes observed in TG and glucose metabolism. Therefore, to gain some understanding 
on the nature of the biochemical changes induced by RGZ, we determined the activity 
and/or expression of some key enzymes involved in glucose and TG metabolism. 
 
The activities of glycerol 3-phosphate dehydrogenase (GPDH), hexokinase (HK), lactate 
dehydrogenase (LDH) and glyceraldehyde dehydrogenase (GAPDH) were determined in 
the cell homogenates. The activities among DMSO (control), insulin, and isoproterenol 
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treated groups were averaged because there was no significant difference in activity (data 
not shown). Consistently, with the increase in glucose consumption and lactate  
 
production induced by RGZ treatment, this study showed that RGZ induced the 
expression, as inferred from the enzyme activities, of HK and LDH (Fig. 8). No 
significant changes were found in the activity of GAPDH. However, the study also 
showed that RGZ increases the activity of GPDH, an enzyme needed for the synthesis of 
G3P and, therefore, for the synthesis of TG. 
 
 
 
 
 
Figure 8. Effect of RGZ on the expression of glycolytic enzymes. Enzymatic 
activities of HK (A), LDH (B), GPDH (C), and GAPDH were determined in cell 
homogenates. Blank bars indicate control (□, no RGZ) and filled bars (■) show RGZ 
treated groups. All data are expressed as mean ±SD. (n=6 for HK, LDH, and GPDH, 
and n=12 for GAPDH. *p<0.05).  
 
 
 
Given the fact that a previous study [71] suggested that RGZ would increase FA re-
esterification due to its effect of the expression of glycerol kinase (GK), we also studied 
the effect of RGZ on the activity of GK and its expression, at the mRNA level. Analysis 
of GK mRNA expression, confirmed the reported study [71], and indicated that RGZ 
enhanced GK expression around 1.5 fold (p<0.01) in adipocytes (Fig. 9A). However, GK 
activity did not show any significant change in response to RGZ or hormone treatments 
(Fig. 9B).  
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Figure 9. Rosiglitazone up-regulates GK expression but not activity.  
Expressions of GK mRNA were determined by RT-PCR (A). The enzyme activity 
of GK is determined using colorimetric assay (B). Blank bars (□) indicate 0h RGZ 
treatment whereas filled bars (■) show samples with 24h RGZ incubation. All data 
are expressed in mean ± SD (n=3, *: p<0.01). 
 
 
 
Possible changes induced by RGZ in the expression of the two main lipases involved in 
the degradation of TG were investigated by western blotting. As shown in the Figure 10, 
adipocytes increased the expression of ATGL in response to RGZ treatment. Expression 
of ATGL was independent of the physiological condition. On the other hand, no changes 
in the expression of HSL were observed. These results suggest that the increase in the 
lipolytic rate observed in RGZ treated adipocytes is, at least in part, due to an increase in 
the expression of ATGL. Similar results on the expression of ATGL had been previously 
reported [87]. 
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Figure 10. Effect of RGZ on the expression of lipases. Western blots against ATGL, 
HSL, and GAPDH (as reference) were performed in cell homogenates (A). The figure 
B shows the relative changes in expression. These were calculated from the average of 
the combined data (control, insulin and isoproterenol). Blank bars (□) indicate control 
(no RGZ) and filled bars (■) show RGZ treated groups. All data are expressed as mean 
±SD (n=3).  
 
 
 
 
Summary  
 
Our studies have shown that RGZ increases the lipolytic activity of adipocytes and, 
concomitantly, it increases the rate of synthesis of TG. This increase in the rate of the 
futile TG cycle requires a major input of energy to re-esterify the excess of fatty acids 
produced [80, 88]. In agreement with this, RGZ treated adipocytes consume higher 
amounts of glucose and produce more lactate. The increase in the rate of the futile cycle 
is asymmetric and biased toward the synthesis of TG. This bias may be responsible for 
the lower output of NEFA observed in RGZ treated adipocytes (Fig.11). 
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In this study we have only determined the activity of a handful of enzymes. However, we 
observed the increase in the expression and activity of ATGL, HK, and LDH. These 
enzymes could explain most of the effects of RGZ on the metabolism of glucose and on 
the hydrolysis of TG. We have not studied most of the enzymes involved in the 
esterification of fatty acids and TG synthesis. However, the increase in GPDH activity 
suggest that part of the increase in the rate of TG synthesis induced by RGZ could be due 
to the increased production of G3P. The lack of increase in GK activity suggests that the 
direct phosphorylation of glycerol may not be responsible for the beneficial effects of 
RGZ.   
 
Overall, the results of these studies are consistent with the effects exerted by RGZ in the 
levels of glucose and NEFA of T2D patients. The results suggest that adipose tissue 
could have a role in improving not only the concentration of NEFA but also in decreasing 
the concentration of glucose in blood. 
 
Although the role of glyceroneogenesis in TG synthesis and RGZ action will be covered 
in the next chapter, the studies shown so far do not support a major role of 
glyceroneogenesis in RGZ action. This inference is supported by the fact that RGZ 
increases the utilization of glucose and the production of lactate. An increase in 
glyceroneogenesis would decrease the utilization of glucose and increase the utilization 
of lactate carbons.  
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Figure 11. The overview of the RGZ-activated pathway for the synthesis of G-G 
from glucose in 3T3L-1 adipocytes.  This figure shows an abbreviated version of 
the metabolic pathway activated by RGZ treatement. Enzymes upregulated in 
response to RGZ including hexokinase (HK), lactate dehydrogenase (LDH), glycerol 
3-phosphate dehydrogenase (GPDH), and adipose triglyceride lipase (ATGL) are 
also shown. The futile cycle accompanied by an increase in lipolysis and re-
esterification is emphasized in dotted allows.  
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CHAPTER IV 
 
 
 
 
 
CONTRIBUTION OF GLYCOLYSIS AND GLYCERONEOGENESIS TO THE 
SYNTHESIS OF GLYCERIDE-GLYCEROL: EFFECT OF RGZ 
 
 
 
Introduction 
 
 
In the previous chapters, we have shown that alterations in glucose and TG metabolism in 
adipocytes could explain the anti-diabetic and NEFA-lowering effects of RGZ. So far, 
two major mechanisms have been proposed to explain the anti-diabetic actions of RGZ: 
glycerol kinase up-regulation [71] and glyceroneogenesis [50, 64]. Both pathways are 
thought to contribute the synthesis of glycerol 3-phosphate (G3P) that eventually serves 
as glyceride-glycerol (G-G) in TG. In addition to these pathways, a third source of 
carbons for the synthesis of G3P is glucose. Since the contribution of glycolysis for the 
synthesis of G3P/G-G has never been investigated, evaluation of the role of glycolysis in 
the synthesis of TG is a main aspect of this chapter. 
 
GK up-regulation in terms of transcription and enzyme activity were observed in human 
and mouse adipose tissues in response to RGZ [71]. However, the degree of contribution 
of GK to the synthesis of G-G in adipocytes has not been investigated. In the previous 
chapter, we showed that the activity of GK does not change after RGZ treatment. On the 
other hand previous studies from other labs were not able to reproduce the reports 
indicating a role of GK in RGZ action [72]. Therefore, we decided not to carry out 
additional studies on the role of GK in RGZ action. 
. 
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Glyceroneogenesis is the pathway involving non-glucose precursors (alanine, pyruvate, 
and lactate) for the synthesis of G3P. Normally this pathway is active in liver in fasting 
condition.  Several studies suggested that this pathway is activated in adipocytes in 
response to RGZ treatment and could represent the main contributor of the anti-diabetic 
effects of the drug. However, the rate of utilization of pyruvate/lactate for the synthesis of 
G-G has not been determined. 
 
We have hypothesized that it is possible to determine in a quantitative fashion the 
contributions of both glycolysis and glyceroneogenesis to the synthesis of glyceride-
glycerol. Accordingly, in this chapter, we show the results of the evaluation of the 
contribution of glycolysis to the synthesis of TG under three lipolytic conditions. 
Moreover, we have examined the effects of RGZ on this contribution. We have also 
evaluated the contribution of glyceroneogenesis to the synthesis of glyceride-glycerol and 
compared it to the contribution provided by glucose metabolism. 
  
 
 
 
Experimental Procedures 
 
 
Metabolism of glucose, lactate/private, and lipids in adipocytes. Fully differentiated 
adipocytes were incubated in the DMEM/10% FBS medium containing either ethanol 
(control) or 500 nM RGZ for 24 hours. After 24 hours, cells were washed in KRBH 
medium containing 6mM glucose and 0.12% FA-free BSA.    The  wash  medium  was  
replaced  with  the  KRBH  incubation medium  containing  either  insulin  (1µg/ml),  
isoproterenol  (1µg/ml),  or  DMSO  (control)  in  addition  to 6.0mM  glucose, 2mM 
lactate,  and  0.12%  FA-free BSA. Upon the replacement of the wash medium with the 
incubation medium,  [U-14C]-glucose  (1.5 to 6µCi/well)  or [U-14C]-lactate (1µCi/well) 
were  added to the assigned wells.  The incubation in the presence of radiolabeled 
substrates proceeded for 1 hour. After this time, the medium was removed and placed on 
ice, and the cells were homogenized in 150 mM Tris buffer containing 50 mM sodium 
chloride (pH 7.5).   
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Calculations for glycolysis. Rates of G-G backbone synthesis (total TG synthesis = de 
novo TG synthesis + TG re-esterification)  from  glucose  were  calculated  from  the  
radioactivity  incorporated  into  lipids  and  the specific activity of glucose. The rates of 
incorporation of glucose carbons into TG, glyceride-glycerol and fatty acids, were 
calculated from the distribution of radioactivity (percentages) among lipid species, and 
between the fatty acyl chains (FA-chain) and glycerol backbone (G-G) of TG.   
 
 
Calculations for glyceroneogenesis. The main problem in estimating the rate of synthesis 
of glyceride-glycerol (G-G) using radiolabeled lactate or pyruvate consists in determining 
the specific activity of any of these compounds in the cells.  
 
In the following paragraphs we describe an approach that was used to obtain estimates of 
the rate of glyceroneogenesis in adipocytes. The partition of pyruvate between the 
pathways of FA synthesis and lactate production can be estimated under any cellular 
condition by incubating the cells with [U-14C]-glucose and determining the radioactivity 
associated with cellular fatty acids and lactate. FAs are isolated from cellular lipids, 
whereas lactate is recovered from the cell culture medium. If, in addition, we know the 
amount of lactate produced during a given time period, the amount of pyruvate used for 
fatty acid synthesis can be estimated from the equation 1: 
 
 
 
 
 
 
 
To estimate the synthesis of glyceride-glycerol from pyruvate, we use the number of 
moles of pyruvate used for FA synthesis, as obtained from the previous equation, and the 
ratio of pyruvate carbons incorporated into FA and G-G that is determined from the 
incubation of the cells with 14C-Lactate.  
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Combining equations 1 and 2: 
 
 
 
 
 
 
 
The previous equations are based on the fact that the production of both lactate and FA 
has pyruvate as a common precursor and, therefore, the ratio of radioactivity associated 
to them is directly proportional to their molar ratio.  
 
According to equation 3 the synthesis of glyceride-glycerol from pyruvate can be 
estimated on the basis of two parallel experiments, one using [U-14C]-glucose and the 
other [U-14C]-lactate. Aside from the difference of the radiotracer used, the cells will be 
incubated under identical experimental conditions, including the concentrations of 
glucose, lactate and hormones.  
 
To estimate the relative contribution of glyceroneogenesis to the synthesis of TG we 
compared the rate of glyceride-glycerol synthesis from glyceroneogenesis with the total 
rate of glyceride-glycerol synthesis.  This means, that we also need to determine the rates 
of incorporation of glucose and glycerol carbons into the glycerol backbone of TG. The 
synthesis of glyceride-glycerol from glucose and glycerol carbons can be estimated from 
the relative incorporation of glucose carbons into G-G and lactate and the amount of 
lactate produced from glucose (Eq. 4).  
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Overall the contribution of glyceroneogenesis to the synthesis of glyceride-glycerol is 
obtained from equations 3 and 4 as:                    
 
 
 
 
 
 
 
 
 
 
 
Equation 5 shows that estimation of the role of glyceroneogenesis is quite simple and 
does not require determining the specific activity of lactate. The simplicity of equation 5 
suggests that these measurements could be characterized by relatively low standard 
errors.   
 
 
Statistics: A) First we calculated the mean value and the standard error of the estimate of 
pyruvate used for FA synthesis (Eq. 1). The experimental values of (cpm FA/cpm Lact), 
lactate produced, and protein mass are obtained for each well in which the cells were 
incubated with 14C-glucose. Values from different wells were averaged and used to 
estimate the standard deviation.  
 
B) The mean values and corresponding standard deviations for the ratio of 14C-lactate 
carbons used for G-G and FA synthesis (cpm G-G/ cpm FA) were estimated from the 
ratio values obtained in individual wells.  
 
C) The amount of pyruvate used for G-G synthesis will be calculated from equation 2, or 
3, by multiplying the means obtained in A and B. The resulting standard deviation will be 
calculated as: 
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SD(C)2 =  [B* SD(A)]2 + [A* SD(B)] 
 
Student t-test was performed for the assessment of statistical significance using Instat 
software (GraphPad Software Inc, La Jolla, CA) 
. 
 
Other Methods. Cell culture, determination of intracellular SAglu, and analysis of lipid 
and metabolites were performed using the procedures described in Chapter II and III. 
 
 
 
 
Results 
 
 
Utilization of glucose for the synthesis of glyceride-glycerol and fatty acids: effect of 
RGZ. To determine the contribution of glycolysis to the synthesis of glyceride-glycerol 
and possible changes induced by RGZ treatment, adipocytes treated with DMSO 
(control) or 500nM RGZ for 24 h were incubated in KRBH containing 6mM [U-14C]-
glucose and 2mM lactate. After 1h incubation with radiolabeled glucose, the medium was 
analyzed to determine the specific activity of lactate. The lipids of the cell homogenates 
were extracted to determine the radioactivity associated to them. The amount of glucose 
used for lipid synthesis was estimated from the specific activity of lactate and the 
radioactivity incorporated into lipids. Subsequent separation of the lipid classes allowed 
determining the fraction of radiolabel present in TG. This information and the 
distribution of radioactivity between the glycerol backbone and the fatty acid chains of 
TG were used to estimate the rates of glyceride-glycerol and fatty acid synthesis from 
glucose.    
 
RGZ induced a significant increase in the amount of glucose incorporated into the total 
lipid fraction in all three conditions, control, insulin and isoproterenol (Fig. 12A). Cells 
incubated with isoproterenol, no insulin, showed the highest increase in glucose 
conversion to lipid.  
 
Estimations of the synthesis of glyceride glycerol from glucose showed that under highly 
lipolytic conditions the cells use increasing amount of glucose to synthesize glyceride-
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glycerol (Figure 12B). The figure also shows that RGZ stimulated the utilization of 
glucose for the synthesis of glyceride-glycerol under the three conditions studied. 
Average increases of G-G synthesis induced by RGZ were 2.7-fold for control (p<0.005), 
2.2-fold for insulin (p<0.005), and 1.5-fold for isoproterenol treated cells (p<0.0005).  
 
The rates of de  novo TG  synthesis from glucose were calculated from the radioactivity 
found in the fatty acids of TG. The results showed that de novo TG synthesis represents a 
small fraction of the glyceride-glycerol synthesized from glucose carbons (Fig. 12C). 
This means that, as expected from the active futile TG cycle that takes place in 
adipocytes, most TG are synthesized from FA previously present in TG.  The data shown 
in Fig 12C also suggest that, in the three lipolytic conditions, RGZ promotes an increase 
in the rate of FA synthesis from glucose in adipocytes.   
 
 
.  
 
 
Figure 12. Utilization of glucose for glyceride-glycerol and fatty acids. A) Rates 
of incorporation of glucose carbons in total lipids; B) rates of synthesis of glyceride-
glycerol from glucose (total TG synthesis); C), de novo TG synthesis (Calculated 
from the moles of stearic acid equivalents synthesized from glucose/3). Blank bars 
(□) show 0 h RGZ treatment and black bars (■) express 24h RGZ incubation. Data is 
shown as mean ± SD (n=6, **: p<0.005, ***: p<0.0005). 
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Utilization of pyruvate for the synthesis of glyceride-glycerol and fatty acids: effect of 
RGZ. To investigate the contribution of glyceroneogenesis for the synthesis of G-G in 
response to RGZ, fully differentiated adipocytes were incubated with 500nM RGZ for 24 
hours. To radiolabel the cellular pool of pyruvate and estimate the utilization of pyruvate 
for fatty acid and glyceride-glycerol synthesis, the cells were incubated in KRBH 
medium containing 6mM glucose, 2mM lactate (cold + radioactive),  and 0.12% BSA.  
 
To calculate the synthesis of glyceride-glycerol from pyruvate we used the equations 2 
and 3 that were described in methods. This calculation requires determining the ratio of 
radioactivity between G-G and FA parts of TG after incubation of the cells with [14C]-
lactate.  The calculation also requires determining the production of lactate, and the 
partition of radiolabeled glucose carbons between FA and lactate. The estimates of the 
rate of G-G synthesis from pyruvate suggested that RGZ does not increase 
glyceroneogenesis. Moreover, the rates of glyceroneogenesis were low under all 
experimental condition tested. As shown in the Figure 13, the maximum rate of G-G 
synthesis from pyruvate was estimated to be around 1.0 nmol/mg.h in RGZ–treated cells. 
This rate is minimal compared to the estimated rates of G-G synthesis from glucose (Fig 
12B).  
 
 
 
Figure 13. Rate of glyceroneogenesis. The rate of the synthesis of G-G from 
pyruvate was estimated using the method described above. ). Blank bars (□) show 0 h 
RGZ treatment and black bars (■) express 24h RGZ incubation. Data is shown as 
mean ± SD (n=6). 
 
 
 
To emphasize the validity of this conclusion the partition of glucose and lactate carbons 
between the FA and G-G of TG were compared and are shown in Figure 14. The study of 
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the distribution of lactate carbons (radioactivity) between the G-G and FA moieties of TG 
indicated that nearly 95% of the lactate carbons are used for the synthesis of FA (Fig. 
14A). Moreover, this fraction did not show significant changes when the cells are 
incubated with RGZ.  A comparison of this data with the partition of glucose carbons 
between the G-G and FA moieties of TG (Fig 14B), shows that the relative utilization of 
glucose carbons for the synthesis of G-G is several times higher than that from lactate. 
Using these data and the equation 5 described in methods, the actual contributions of 
glyceroneogenesis to the synthesis of glyceride-glycerol were estimated (Fig. 14C).  
 
These results showed that under any of the experimental conditions studied, the 
contribution of glyceroneogenesis to the synthesis of glyceride-glycerol is less than 6%. 
Moreover, as also shown in the Figure 13C, the contribution of glyceroneogenesis is not 
increased by RGZ.  
 
 
 
 
Figure 14. Contribution of glyceroneongenesis for the synthesis of G-G in 
adipocytes. Partition of [U-14C]-glucose (A) and lactate (B) carbon into G-G and 
FA-chain were measured, and ratio is expressed.  Contribution of glyceroneogenesis 
over glycolysis was also estimated (C). The empty bars (□) show 0h incubation with 
RGZ whereas the filled bars (■) indicate incubation with 500nM RGZ for 24 hours. 
All data is expressed in mean ± SD (n=6). 
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Effect of pyruvate on the metabolism of adipocytes. Previous studies from other labs 
suggested that glyceroneogenesis was important in human and rodent adipocytes. These 
studies used a high concentration of pyruvate (25mM) and as previously mentioned they 
did not determine rates of glyceroneogenesis [65, 67]. However, normal physiological 
concentration of pyruvate in human blood is around 0.02 to 0.15 mM [89, 90].  
 
To determine the impact of pyruvate concentration on the metabolism of TG in 
adipocytes, the cells were incubated in KRBH medium containing different 
concentrations of pyruvate (0, 2, and 10mM) along with 6mM glucose, 0.12% BSA, and 
hormones (insulin or isoproterenol) for 1 hour. Analysis of the medium revealed that 
adipocytes in high lipolytic state (isoproterenol) produce more NEFA in response to the 
increase in pyruvate concentration (Fig. 15A). Moreover, suppression of lipolysis was 
observed in the cells incubated with pyruvate in both experimental conditions, 
isoproterenol or insulin (Fig. 15B). Although pyruvate did not significantly increase 
NEFA release in the presence of insulin, considering that it decreased the rate of 
lipolysis, it still promoted a relative increase in the production of NEFA (Fig. 15C). 
 
These results indicate that pyruvate enhances NEFA production although it suppresses 
lipoylsis in adipocytes. In adipocytes most of NEFA usually originates from lipoylsis. 
Therefore these results show that excess pyruvate impairs normal metabolic activity in 
adipocytes. This action of pyruvate on adipocytes is pro-diabetic. The altered metabolic 
activity that enhances NEFA production even at low lipolytic rates would worsen the 
existing diabetic condition.   
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Figure 15. Relative NEFA production is increased in response to pyruvate. 
Adipocytes, incubated with different concentration of pyruvate along with 6mM 
glucose and 0.12% FA-free BSA for 1 hour were analyzed for NEFA production (A) 
and glycerol release (B) in the high lipolytic (isoproterenol) and low lipolytic 
(insulin) conditions. The degree of NEFA output relative to glycerol release 
(lipolysis) was also estimated (C). Data is shown in mean ± SD (n=2, *: p<0.05, 
**:p<0.005 compared to 0mM pyruvate).  
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Summary 
 
Synthesis of G3P, ultimately serves as glyceride-glycerol (G-G) of TG, is one of the rate 
determining steps for FA re-esterfication that can contribute anti-diabetic effects exerted 
in adipocytes. In this chapter we investigated the roles of glycolysis and 
glyceroneogenesis in the synthesis of G-G and the effects of RGZ in the relative 
contributions of these pathways.  
 
The estimated rates of glyceroneogenesis (G-G synthesis from pyruvate) suggest that the 
overall contribution of this pathway to the synthesis of G-G is minor (maximam ~5% in 
basal, non drug treated cells) as compared to the contribution of glycolysis. In addition, 
the treatment of adipocytes with RGZ did not have a major effect on the rates of the G-G 
synthesis from pyruvate in either lipolytic state. In the cells in high lipolytic state, in 
which glyceroneogesis was thought to have a major contribution to the synthesis of G-G, 
the amount of G-G synthesized from pyruvate was minimal (0.6 - 0.7% of the overall 
contribution). These results indicate that glyceroneogenesis may not have a significant 
role during fasting or in the anti-diabetic actions induced by RGZ in adipocytes. 
 
Furthermore, our studies suggest that RGZ promotes a significant increase in the rate of 
glycolysis and, accordingly, an increase in the synthesis of G-G from glucose regardless 
the lipolytic states of adipocytes. Now we can speculate that the increase in glucose 
catabolism and use of glucose for the synthesis of G-G could be responsible of the higher 
rate FA re-esterification and, thus, of the lower output of NEFA. 
 
 
 45
CHAPTER V 
 
 
DISCUSSION 
 
 
 
Summary of the Study 
 
Excess of circulating NEFA has been linked to toxic effects that contribute to the 
development of type II diabetes (T2D) [32, 35, 91, 92]. Being the largest FA storage and 
buffering site through lipolysis and esterification in the mammalian body, adipocytes 
have potential to contribute to both the prevention and development of T2D. The anti-
diabetic agent, rosiglitazone (RGZ), is an agonist of the transcription factor PPAR-γ that 
is mainly expressed in adipocytes. The known effects of the drug include normalization 
of excess NEFA, thereby improving insulin sensitivity in muscle and liver, and glucose 
levels. This anti-diabetic action of the drug is thought to be induced by changes in 
adipocytes. 
 
To understand the mechanism of action of RGZ, we investigated some aspects of the 
metabolism of glucose, pyruvate and TG using mouse 3T3L-1 adipocytes in this study. 
 
The major findings of this study are the following: 
 
• The rate of glucose and TG metabolism in 3T3L-1 adipocytes can be directly 
determined using specific activity (cpm/nmol) of lactate released into the medium. 
 
• Adipocytes display various changes depending on the condition of incubation. 
Isoproterenol-treated adipocytes increase glucose consumption in the absence of 
insulin. Furthermore, the increased rate of lipolysis in these adipocytes facilitates 
the synthesis of G-G of TG using glucose carbons. 
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• RGZ increases the rate of two opposite pathways, lipolysis and FA uptake and re-
esterification, in adipocytes regardless of the conditions of incubation (basal, low 
lipolytic, and high lipolytic states).  
 
• RGZ increases the rate of the futile cycle of TG in a synthesis biased fashion. This 
could explain why RGZ treated adipocytes have a reduced output of NEFA. 
 
• RGZ-treated adipocytes utilize larger amounts of glucose for the synthesis of G-G 
and this may be the cause of the enhanced rate of FA re-esterification.  
 
• The greater utilization of glucose for G-G synthesis would be possible, at least in 
part, because RGZ up-regulates the expression of HK, LDH, GPDH, and ATGL. 
 
 
• These studies suggest that neither glyceroneogenesis nor GK play significant roles 
in NEFA lowering effect of RGZ. 
 
 
Overall the findings in this study provide new insights to the lipid metabolism of 
adipocytes and NEFA lowering effects of RGZ. 
 
 
 
Rosiglitazone and Metabolism of Adipocytes 
 
In this study it was found that upon incubation with RGZ adipocytes simultaneously up-
regulate several metabolic pathways regardless the conditions of incubation (basal, low 
lipolysis and high lipolysis). These include lipolysis, glucose uptake, G-G synthesis from 
glucose, and FA re-esterification. Furthermore, the results of the rate estimations of 
glucose and TG metabolism in this study indicate that RGZ activates cycling of lipolysis 
and FA re-esterification through enhancement of G-G synthesis from glucose.  
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RGZ, through binding on PPAR-γ, either directly or indirectly regulates the transcription 
of genes to exert its anti-diabetic effect in adipocytes. We observed increases in activities 
of HK, LDH, and GPDH. These proteins relate to the synthesis of G3P that eventually 
ends up in G-G of TG. Up-regulation of these enzymes is positively correlated to the rate 
of the lipid metabolism estimated in this study. Also, analysis of protein expression 
suggested that ATGL, but not HSL, is up-regulated by RGZ incubation for 24 hours in 
adipocytes. According to the estimations of FA and G-G synthesis rates and the rate of 
re-esterification, RGZ-treated adipocytes use most of glucose for the synthesis of G-G 
instead of FA in all physiological condition. 
 
 
Enhanced expression of ATGL supported the increased rate of lipolysis even in the 
presence of insulin. Although phosphorylation of HSL is inhibited by insulin, ATGL still 
exert its activity. Previous studies suggested that rate of re-esterification tend to be higher 
in lipolytic state, however, none of them directly estimated the rate of G-G synthesis. 
Enhancement of G-G synthesis pathway rather than FA synthesis may be the way of 
adipocytes to control the amount of FA release.  
 
 
 
Lipolysis and FA Oxidation 
 
Along with this study, several others have also confirmed that RGZ enhances lipolysis in 
adipocytes [87, 93-95]. Up-regulation of ATGL protein expression explains the increase 
rate of lipolysis in RGZ-treated adipocytes even in the presence of insulin. However, 
several studies showed the insulin reduces mRNA expression of ATGL and controls the 
rate of lipolysis [94-96]. Perhaps the down-regulation of ATGL protein expression was 
not seen in this study because insulin treatment lasted only 1 hour after the 24 hours 
incubation with RGZ.  However, it seems that insulin did not acutely affect the activity of 
ATGL which was already expressed in response to RGZ. In other words, enhanced 
lipolysis in RGZ-treated adipopcytes in basal, low lipoyltic, and high lipolytic states 
suggest that ATGL, once expressed, is not regulated by hormones. T2D patients usually 
take RGZ in the presence of insulin. The effect of co-existing insulin and RGZ for long 
period of time in terms of ATGL expression and activity still remains to be investigated.  
 
The results of this study showed that expression of HSL is not up-regulated by RGZ. 
However there are other studies showing a positive effect of RGZ on HSL expression 
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[97, 98]. Still, HSL is activated by phosphorylation via cAMP-activated protein kinase 
(PKA)[48], and this is suppressed in the presence of insulin. Therefore enhanced lipolysis 
in the cells treated with insulin is less likely due to the activity of HSL. This makes 
ATGL the major contributor for the higher rate of lipolysis in RGZ treated adipocytes. 
 
 
In terms of lipid metabolism, it has been shown that the degree of lipolysis induced by 
isoproterenol is proportional to the rate of FA re-esterification in adipocytes [42, 50, 99]. 
Estimated rate of enhanced G-G synthesis from glucose in the presence of isoproterenol 
and RGZ is in agreement with those studies. Furthermore, although there have been 
implications of increased G-G synthesis in response to lipolysis in adipocytes, our study 
is the first to directly estimate the rate of G-G synthesis from glucose. 
 
The major consequence of the increased rate of lipolysis in adipocytes that has been 
known for long time is reduction in ATP level [80, 100-103]. Since oxidation of one 
molecule of palmitate (16C FA) can generate up to ~129 ATPs, lower ATP levels  
indicate that adipocytes do not undergo efficient oxidative phosphorylation of FA for 
ATP production under lipolytic condition [80]. Probably this is because adipocytes’ 
major role is to provide FA as energy to other tissues at the time of starvation. Another 
implication is the increased rate of FA re-esterification in adipocytes under lipolytic 
condition increases the need for ATP for FA re-esterification. Since this process requires 
a large input of ATP (7-9 ATP for re-esterification of 3FAs and production of G3P), 
under inefficient/slow FA oxidative phosphorylation, re-esterification of FA seems to 
contribute to a significant loss of ATP (increased AMP:ATP ratio) in adipocytes [80, 88]. 
This explains the larger amount of lactate production in isoproterenol and RGZ-treated 
adipocytes. Increased production of lactate from adipocytes in response to lipolytic 
condition indicates the cells undergo anaerobic glycolysis to generate ATP at a faster rate 
to meet ATP requirement for FA re-esterification.  
 
Larger increases in glucose consumption and lactate production in RGZ-treated 
adipocytes in all conditions suggest that RGZ does not enhance efficient FA oxidation to 
produce ATP. In other words, rate of re-esterification is much faster than rate of FA 
oxidation in adipocytes. In this study, we observed a tendency of reduction in 
intracellular FA level even in the increase in lipolysis and reduction in NEFA output in 
RGZ-treated adipocytes. This might be solely due to increased re-esterification rate. 
However, up-regulation in mRNA expressions of uncoupling protein (UCP) and proteins 
relating to FA oxidation (carnitine acetyltransferase, acetyl-CoA acyltransferase, 
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cytochrome oxidase c) have been reported in adipocytes incubated with RGZ [62, 104]. 
Furthermore, adipocytes from RGZ-treated mouse showed a significant increase in O2 
consumption [105].Therefore there might be enhancement of FA oxidation in these cells 
for increased NADH production. In addition, RGZ may increase uncoupling of the 
electron transport chain and ATP synthase in mitochondria to prevent further ATP 
synthesis. These would contribute lowering intracellular FA level and increased glucose 
uptake for ATP synthesis.   
 
 
However, according to the results from this study, we still expect that the contribution of 
FA oxidation in response to RGZ remains minimal compared to increased rate of FA re-
esterification using glucose carbons because of increased glucose consumption and 
lactate output. 
 
 
 
Glycolysis and G-G synthesis 
 
Adipose glucose transporter protein, GLUT-4, has been shown to increase by RGZ 
treatment in mouse and human adipocytes, supporting increased glucose uptake by RGZ-
treated adipocytes observed in this study. Levels of mRNA expressions of other 
glycolytic enzymes, including phosphofructokinase, pyruvate dehydrogenase subunit α 
and LDH, were also resported to be up-regulated in mouse adipose tissue by RGZ [106]. 
Several other studies have shown the increase in glucose uptake by adipocytes/adipose 
tissues. 
 
Taken together with the increase in HK enzyme activity and increased glucose uptake 
regardless of condition of incubation, these data suggest that RGZ directly facilitates 
glucose consumption by adipocytes independent of the condition of incubation. In 
addition to facilitation of lipolysis, up-regulation of GPDH activity by RGZ supports 
enhanced rate of re-esterification via synthesis of G3P (G-G) from glucose. Moreover, 
the rate of GPDH was not affected by the hormones (data not shown), suggesting this 
enzyme is not acutely regulated by insulin or isoproterenol. Increased enzymatic activity 
of LDH is strong evidence of anaerobic glycolysis in RGZ-treated adipocytes. As 
mentioned above, this is most likely driven from ATP requirement imposed by enhanced 
lipolysis and re-esterification in the cells incubated with this drug.  
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FA Synthesis and Esterification 
 
As mentioned above, the rate of lipolysis has a positive correlation with rate of re-
esterification. Obviously, lipolysis alone does not explain RGZ’s NEFA lowering action 
since cells incubated with isoproterenol increase NEFA release compared to adipocytes 
treated in insulin or DMSO (control). The rate estimation in this study revealed that 
RGZ-treated adipocytes undergo faster re-esterification over increase in lipolysis rate. 
This indicates that RGZ itself also increases FA re-esterification and NEFA uptake in 
adipocytes using processes that is not regulated by lipolysis.  
 
Although we did not measure activity or expression of proteins relating to FA 
esterification and FA transport, several studies have resported the positive effect of RGZ 
on mRNA expressions of enzymes relating to those actions in adipocytes. These include 
acyl-CoA synthase (ACS) [62, 105], glycerol 3-phosphate acyltransferase (GPAT) [106], 
diacylglycerol acyl transferase (DGAT) [107, 108], and FA transporter protein 
(FAT/CD36) [62]. Along with increased GPDH activity in reponse to RGZ, these 
findings further support that RGZ facilitates FA re-esterification by up-regulating several 
proteins independent of condition of incubation. 
 
The results from the present study showed that adipocytes treated with RGZ increases FA 
synthesis in some extent, but the amount of FA synthesized from glucose remains 
relatively small. Similar to the expression of proteins relating to FA esterification, studies 
of expression of enzymes relating to FA synthesis have also shown several proteins that 
are up-regulated by RGZ. Increased mRNA expression of adipose fatty acid synthase 
(FAS) in response to RGZ was reported [107]. Elevated level of protein expression of 
acetyl-CoA carboxylase (ACC), an enzyme catalyzing initial step of FA synthesis, was 
also found in adipose tissue in rat treated with RGZ and high fat diet along with decrease 
in AMP activated protein kinase (AMPK) level [109]. These results suggest that RGZ 
enhances FA synthesis in adipocytes. However, since ATP level in adipocytes incubated 
with RGZ is expected to be low, AMPK should be active and inhibit ACC in the 
experimental setting of this study. Therefore, ACC activity might be enhanced to some 
extent in RGZ-treated adipocytes, but this would not result in production of a large 
amount of FA.  
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Glyceroneogenesis and Glycerol Kinase 
 
GK enzyme assay and the estimation of G-G synthesis from lactate/pyruvate indicated 
that GK up-regulation and glyceroneogenesis do not contribute enhancement of G-G 
synthesis to lower NEFA in plasma in the adipocytes treated with RGZ in any 
physiological states.  
 
Rates or expressions of phosphoenol pyruvate carboxylase-C (PEPCK-C) and pyruvate 
carboxylase (PC) in adipocytes were not investigated in this study. Several studies have 
shown there are increases in gene expression or activity of those enzymes in response to 
RGZ in adipocytes [68, 104, 105, 110].  Also, as mentioned in Chapter I, the studies 
supporting up-regulation of glyceroneogenesis have shown increased incorporation of 
pyruvate carbons in lipid and TG fractions in adipocytes under high pyruvate 
concentration [65, 67, 68].  
 
The results in the present study suggest high concentration of pyruvate induces pro-
diabetic effects in adipocytes by increasing NEFA release even in the absence of 
lipolysis.  Moreover, the estimated rate of G-G synthesis from pyruvate indicates that 
contribution of glyceroneogenesis for the synthesis of G-G is minimal compared to G-G 
synthesized from glucose.  
 
 
. 
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Findings and Conclusions:   
 
To gain better understanding of the action of the anti-diabetic drug, rosiglitazone (RGZ), 
we investigated some aspects of the metabolism of glucose, pyruvate and TG in mouse 
3T3L-1 adipocytes. 
 
The major findings of this study include: 1) The rate of glucose and TG metabolism in 
3T3L-1 adipocytes can be directly determined using specific activity (cpm/nmol) of 
lactate released into the medium, 2) Adipocytes display various changes depending on 
the condition of incubation. Isoproterenol-treated adipocytes increase glucose 
consumption in the absence of insulin. Furthermore, the increased rate of lipolysis in 
these adipocytes facilitates the synthesis of G-G of TG using glucose carbons, 3) RGZ 
increases the rate of two opposite pathways, lipolysis and FA uptake and re-esterification, 
in adipocytes regardless of the conditions of incubation (basal, low lipolytic, and high 
lipolytic states, 4) RGZ increases the rate of the futile cycle of TG in synthesis biased 
fashion. This could explain why RGZ treated adipocytes have a reduced output of NEFA, 
5) RGZ-treated adipocytes utilize larger amounts of glucose for the synthesis of G-G and 
this may be the cause of the enhanced rate of FA re-esterification. The greater utilization 
of glucose for G-G synthesis would be possible, at least in part, because RGZ up-
regulates the expression of HK, LDH, GPDH, and ATGL, and 6) Neither 
glyceroneogenesis nor GK play significant roles in NEFA lowering effect of RGZ. 
 
Overall the findings in this study provide new insights to the lipid metabolism of 
adipocytes and NEFA lowering effects of RGZ. 
